Medicine and Dentistry
Mycosis fungoides
100%
Dermatological Agent
47%
Adverse Event
46%
Cutaneous T Cell Lymphoma
38%
Radiation Therapy
38%
Brentuximab Vedotin
34%
T Cell
34%
Monoclonal Antibody
29%
Lymphoproliferative Disease
24%
Quality of Life
22%
Immune Checkpoint Blockade
22%
Mogamulizumab
22%
Immune Checkpoint Inhibitor
22%
Cancer
21%
Immunotherapy
18%
Cancer Therapy
17%
Antibody Therapy
15%
Lichenoid Eruption
15%
Neoplasm
15%
Clear Cell Renal Cell Carcinoma
14%
Arm
14%
Melanoma
14%
Vorinostat
13%
Differential Diagnosis
13%
Stem Cell Transplant
13%
Transplantation
13%
Lymphomatoid Papulosis
12%
Lichenoid
12%
Diseases
12%
Immune-Related Adverse Events
12%
Transcription Factor GATA 3
12%
Malignant Neoplasm
11%
Hematopoietic Stem Cell Transplantation
11%
Ribavirin
11%
Biological Therapy
11%
Sorafenib
11%
Programmed Death-Ligand 1
11%
Eosinophilic
11%
Hodgkin's Lymphoma
11%
Kaposi Sarcoma
11%
Hidradenitis Suppurativa
11%
Diagnostic Error
11%
Central Nervous System
11%
Blister
11%
Metastatic Melanoma
11%
Vesicular Rash
11%
Wart Virus
11%
Upregulation
11%
Cellulitis
11%
Bloodstream Infection
11%
Keyphrases
Mycosis Fungoides
99%
Radiotherapy
26%
Checkpoint Inhibitors
26%
Cutaneous Adverse Drug Reactions (cADRs)
25%
Romidepsin
22%
Brentuximab Vedotin
22%
Radiation Therapy
22%
Immune Checkpoint Inhibitors
20%
Complete Response
19%
Advanced Stage
18%
Complete Remission
17%
Relapsed or Refractory
17%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
CD30+
14%
Renal Cell Carcinoma
14%
Clinical Benefit
14%
Differential Diagnosis
13%
T-cell Lymphoma
13%
Lymphomatoid Papulosis
13%
Monoclonal Antibody
12%
Immune-related Adverse Events
12%
GATA3
12%
Immunohistochemical Expression
12%
Central Nervous System Involvement
11%
HIV-negative
11%
Antibody-based
11%
Molecular Features
11%
Combination Immunotherapy
11%
Ribavirin
11%
Incidence Management
11%
Monotherapy
11%
Concurrent Radiation
11%
Associated Proteins
11%
CD30+ Lymphoproliferative Disorders
11%
Biologic Therapy
11%
Metastatic Melanoma
11%
CD4+ T Cells
11%
Anti-PD-1 Antibody Therapy
11%
Hidradenitis Suppurativa
11%
Long-term Maintenance
11%
Dermatologic Toxicity
11%
Programmed Death-ligand 1 (PD-L1)
11%
Immune Checkpoint Inhibitor Therapy
11%
Single Institution Study
11%
Aerosolized
11%
Peripheral Blood
11%
Lymphoma
11%
Sorafenib
11%
Morphological Characteristics
11%
Immunophenotypic Profile
11%
Pharmacology, Toxicology and Pharmaceutical Science
Cutaneous T Cell Lymphoma
65%
Brentuximab Vedotin
34%
Tenalisib
34%
Adverse Event
34%
Mycosis fungoides
33%
Syndrome
25%
Romidepsin
22%
T Cell Lymphoma
20%
Malignant Neoplasm
17%
Hepatotoxicity
11%
Methicillin-Resistant Staphylococcus Aureus
11%
Ribavirin
11%
Skin Cancer
11%
Infectious Agent
11%
Monotherapy
11%
Lymphomatoid Papulosis
11%
Receptor Agonist
11%
Hypericin
11%
Randomized Clinical Trial
11%
Hydrochlorothiazide
11%
Photodynamic Therapy
11%
Skin Toxicity
11%
Hodgkin Disease
11%
Serotonin Syndrome
11%
NK T Cell Lymphoma
11%
Chimeric Antigen Receptor
11%
Diseases
9%
Neuropathy
9%
Staphylococcus aureus
8%
Chemotherapy
8%
Respiratory Syncytial Virus Infection
7%
Progression Free Survival
7%
Toll Like Receptor Agonist
6%
Biological Product
6%
Placebo
6%
Flow Cytometry
6%
Melanoma
5%
Neoplasm
5%
Clinical Trial
5%